Patents Examined by Eggerton Campbell
-
Patent number: 5573914Abstract: A process for detecting the presence or absence of a specific nucleic acid sequence or antibody in a sample using an oligonucleotide to bind to the nucleic acid sequence or antibody to be detected, forming double-stranded nucleic acid sequence using the bound oligonucleotide in conjunction with another oligonucleotide or DNA synthesis, synthesizing RNA transcripts from the thus-formed double-stranded nucleic acid sequence, and detecting the existence of the RNA transcripts, and oligonucleotides and kits useful in carrying out such a process.Type: GrantFiled: May 15, 1995Date of Patent: November 12, 1996Assignee: Gen Trak, IncInventor: Jack D. Love
-
Patent number: 5573905Abstract: The present invention describes an encoded combinatorial chemical library comprised of a plurality of bifunctional molecules having both a chemical polymer and an identifier oligonucleotide sequence that defines the structure of the chemical polymer. Also described are the bifunctional molecules of the library, and methods of using the library to identify chemical structures within the library that bind to biologically active molecules in preselected binding interactions.Type: GrantFiled: March 30, 1992Date of Patent: November 12, 1996Assignee: The Scripps Research InstituteInventors: Richard Lerner, Kim Janda, Sydney Brenner
-
Patent number: 5573908Abstract: A recombinant cell comprising a host cell containing a recombinant DNA sequence is disclosed. The recombinant DNA sequence comprises vector DNA and DNA which encodes a mammalian adrenergic receptor. The host cell is one capable of undergoing proliferation in response to activation of the adrenergic receptor. In one specific embodiment of the foregoing, the adrenergic receptor includes a mutation in the third cytoplasmic loop thereof which renders the adrenergic receptor constitutively active, and the host cell undergoes proliferation in response to the constitutively active adrenergic receptor. Also disclosed are in vitro assays employing the foregoing which are useful for screening test compounds for antitumor and antiatherogenic activity, along with a diagnostic assay for detecting the oncogenic activation of cells in a patient.Type: GrantFiled: December 20, 1993Date of Patent: November 12, 1996Assignee: Duke UniversityInventors: Lee F. Allen, Robert J. Lefkowitz, Marc G. Caron, Susanna Cotecchia
-
Patent number: 5569754Abstract: The invention relates to small RNAs encoded within the nucleus of mammalian cells that specifically import to the mitochondria. The RNAs bind to several nucleolar peptides and thus provide potential carriers for import of biological molecules, including metabolites and proteins, into the mitochondrial compartment. Mitochondrial dysfunction in several maternally inherited human diseases may be correctable employing linkage of mitochondrial import signal to mitochondrial tRNA sequences expressed from nuclear trans-genes without requirement for direct genetic transformation of mitochondria.Type: GrantFiled: June 11, 1993Date of Patent: October 29, 1996Assignee: Board of Regents, University of TX SystemsInventors: R. Sanders Williams, Kang Li
-
Patent number: 5567585Abstract: A silver staining method is provided for staining an organic molecule capable of binding silver. An improved image is developed and visualized. A kit useful in practicing the method is described. A permanent record of the image of the profile of the stained molecules is obtained.Type: GrantFiled: June 9, 1994Date of Patent: October 22, 1996Assignee: The University of Tennessee Research CorporationInventors: Gustavo Caetano-Anolles, Brant J. Bassam, Peter M. Gresshoff
-
Dimeric fluorescent energy transfer dyes comprising asymmetric cyanine azole-indolenine chromophores
Patent number: 5565554Abstract: Novel fluorescent DNA-staining dyes are provided combining asymmetric cyanine azole-indolenine dyes, which provide for strong DNA affinity, large Stokes shifts and emission in the red region of the spectrum. The dyes find particular application in gel electrophoresis and for labels which may be bound to a variety of compositions in a variety of contexts.Type: GrantFiled: July 29, 1994Date of Patent: October 15, 1996Assignee: The Regents of the University of CaliforniaInventors: Alexander N. Glazer, Scott C. Benson -
Patent number: 5556772Abstract: The subject invention provides novel compositions containing a mixture of (a) an enzyme that possesses substantial 3'-5' exonuclease activity (b) a DNA polymerase with less 3'-5' exonuclease activity than the enzyme with substantial 3'-5' exonuclease activity. Preferably, the DNA polymerase for inclusion in the compositions are DNA polymerases that substantially lack 3'-5' exonuclease activity. A preferred embodiment of the invention is a composition comprising the Taq DNA polymerase (isolated from Thermus aquaticus) and the Pfu DNA polymerase (isolated from Pyrococcus furiosus). Another aspect of the invention is to provide methods for synthesizing polynucleotides, typically DNA, using compositions comprising an enzyme that possesses substantial 3'-5' exonuclease activity and a DNA polymerase with less 3'-5' exonuclease activity than the enzymes possessing substantial 3'-5' exonuclease activity, preferably a DNA polymerase that substantially lacks 3'-5' exonuclease activity.Type: GrantFiled: February 16, 1994Date of Patent: September 17, 1996Assignee: StratageneInventors: Joseph A. Sorge, Rebecca L. Mullinax
-
Patent number: 5543292Abstract: A process for detecting the existence of at least one sequence of oligonucleotide in a nucleic acid sample includes at least one performance of a step of mixing the sample witha labeled common polynucleotide, anda polynucleotide probe comprising a sequence complementary to at least a part of the sequence of oligonucleotide and a sequence complementary to at least a part of the labeled common polynucleotide. The existence of a sequence of oligonucleotide which is an analyte existing in a nucleic acid sample can be detected by the use of a common reagent and an unattached polynucleotide having a base sequence specific for the analyte to be measured.Type: GrantFiled: June 14, 1993Date of Patent: August 6, 1996Assignee: Hitachi, Ltd.Inventors: Kyoko Imai, Kazumichi Imai, Yasushi Nomura
-
Patent number: 5543509Abstract: A method for the quantifying of human and murine laminin mRNA transcripts of the A, B1 and B2 chains, and of human and murine .beta.-actin mRNA, entails utilizing particular types of PCR primers and control cRNA.Type: GrantFiled: August 14, 1992Date of Patent: August 6, 1996Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Paul E. Klotman, Leslie A. Bruggeman, Satoshi Horikoshi
-
Patent number: 5539096Abstract: The present invention relates to polynucleotide sequences and proteins that are differentially expressed in invasive or metastasis cancer cells during malignant tumor progression of cancer, for example in rhabdomyosarcoma and which may thus serve as general molecular markers in metastatic disease as well as providing a basis for therapy. The present invention also relates to a method of diagnosis of malignant diseases based on the detection of such markers.Type: GrantFiled: September 8, 1994Date of Patent: July 23, 1996Assignee: Universite de MontrealInventors: Feridoun Babai, Luc Daigneault, Andre Royal
-
Patent number: 5529900Abstract: A method of screening for glucocorticoid remediable aldosteronism (GRA) in a mammal by detecting the presence or absence of a chimaeric gene duplication resulting from unequal crossing over of the 11, .beta.-hydroxylase and aldosterone synthase genes, or the product encoded by the chimaeric gene duplication. Presence of the chimaeric gene duplication or its encoded product is indicative of a mammal afflicted with GRA and absence of the chimaeric gene duplication or its product is indicative of a mammal not afflicted with GRA.Type: GrantFiled: January 8, 1993Date of Patent: June 25, 1996Assignees: Brigham and Women's Hospital, University of UtahInventors: Richard P. Lifton, Jean-Marc Lalouel
-
Patent number: 5525714Abstract: The invention relates to a polypeptide containing a sequence of contiguous amino acids of the polypeptide sequence coded by exon 17 of the cDNA of the APP 770 gene, with said sequence of contiguous amino acids being such that:it has from 5 to the total number of amino acids coded by said exon 17,and it contains the amino acid corresponding to codon 692 in the cDNA of the APP 770 gene and which is alanine substituted for glycine. (no figure).Type: GrantFiled: October 8, 1993Date of Patent: June 11, 1996Assignee: N. V. Innogenetics S.A.Inventors: Christine Van Broeckhoven, Jean-Jacques Martin, Lydia Hendriks, Patrick Cras
-
Patent number: 5525492Abstract: The present invention is directed to a process for HLA typing in polymorphic systems by polymerase chain reaction of the nucleic acids. More specifically, the oligonucleotide primers and probes are drawn to the alpha domain of the HLA gene.Type: GrantFiled: May 14, 1993Date of Patent: June 11, 1996Assignee: ISIS Innovation, Ltd.Inventor: Adrian V. S. Hill
-
Patent number: 5523206Abstract: A new process and kit are described that combines methods for generating the nucleotide base sequence of a DNA molecule with an ultra-sensitive silver staining protocol. This new combination of technologies allows for a direct, non-instrument based visualization of electrophoretically separated sequencing fragments. This non-radioactive system includes sequencing the DNA molecule by forming a set of fragments using an enzymatic dideoxy-mediated chain termination method, electrophoretically separating the DNA fragments on a gel medium, and exposing the gel medium to ultra-sensitive silver-staining solutions for a time determined by viewing the silver stain reacted primer extension products.Type: GrantFiled: March 23, 1994Date of Patent: June 4, 1996Assignee: Promega CorporationInventors: Leopoldo G. Mendoza, Douglas R. Storts
-
Patent number: 5523388Abstract: The invention provides a method of synthesizing oligonucleotides having random tuplets using individual monomers. The steps consist of: (1) sequentially coupling monomers on separate supports to form at least two different tuplets, the coupling is performed in separate reaction vessels; (2) mixing the supports from the reaction vessels; (3) dividing the mixed supports into two or more separate reaction vessels; and (4) repeating steps (1) through (3) one or more times in the reaction vessels of step (3), wherein the last step ends at step (2). Additionally, the oligonucleotides can be cleaved from the supports.Type: GrantFiled: February 27, 1995Date of Patent: June 4, 1996Assignee: Ixsys, Inc.Inventor: William D. Huse
-
Patent number: 5516630Abstract: Methods for producing HAV cDNA, products thereof, and uses thereof, are described. HAV cDNA is produced, for example, by reverse transcribing HAV RNA and subsequently inserting the HAV cDNA into bacterial plasmids by genetic-engineering techniques. Transformed bacteria are then cloned and cultured to produce replicated chimetic plasmids containing the HAV cDNA. Such HAV cDNA is useful in assaying for the presence of HAV and in the production of HAV antigen and in the production of antibodies against HAV.Type: GrantFiled: November 6, 1991Date of Patent: May 14, 1996Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: John R. Ticehurst, David Baltimore, Stephen M. Feinstone, Robert H. Purcell, Vincent R. Racaniello, Bahige M. Baroudy
-
Patent number: 5512436Abstract: Hybridization buffers, for hybridizing complementary polynucleotides, contain polyvinyl alcohol (MW 1000-20000) and/or polystyrene sulphonic acid (e.g. MW 60000-80000) as a rate enhancer, generally at a concentration of 1-10%. Dextran sulphate, polyethylene glycol and cationic detergents may be additionally present. The method is useful when one of the two complementary polynucleotides is immobilised, or is in in situ hybridizations.Type: GrantFiled: September 2, 1993Date of Patent: April 30, 1996Assignee: Amersham International plcInventor: Timothy Stone
-
Patent number: 5506098Abstract: A method of identifying the presence of a known target sequence in double-stranded DNA contained in a fixed cellular or subcellular biological structure. By adding a stable, reporter-labeled RecA/single-stranded probe complex to the structure, the target sequence can be effectively labeled by in situ hybridization, allowing the target sequence to be visualized histologically and microscopically or detected by in situ cytometry or cell sorting flow techniques.Type: GrantFiled: September 4, 1991Date of Patent: April 9, 1996Assignee: Daikin Industries, Ltd.Inventors: David A. Zarling, Cornelia J. Calhoun, Elissa P. Sena
-
Patent number: 5506103Abstract: Disclosed is a method for detecting and quantitating oligonucleotides with charged internucleotide linkages in biological fluids. In this method, a biological fluid sample is contacted with an anion exchange resin at from 40.degree. C. to 65.degree. C. for a time sufficient to enable oligonucleotides in the sample to adsorb to the resin. The absorbed oligonucleotides are then desorbed with a buffer having a salt concentration of about 1 M to 2.5 M and a pH in the range of about 6.5 to 7.5, the desorption being performed at about 40.degree.-65.degree. C. The oligonucleotides so released are then detected and quantitated.Type: GrantFiled: November 16, 1993Date of Patent: April 9, 1996Assignee: Hybridon, Inc.Inventors: Aharon S. Cohen, Andre Bourque
-
Patent number: 5506350Abstract: Techniques for producing cloned DNA sequences are provided which sequences are complementary to DNA occurring in one selected region of one chromosome of a multi-chromosomal genome, such as the human genome. Such cloned DNA sequences can be labeled and formed into probes by conventional procedures, there are provided methods for making probe compositions which comprise mixed DNA segments derived from such a DNA sequence. An improved DNA sequence transamination procedure is provided utilizing trifluoroacetate chaotrope anions. With high concentrations of low complexity DNA, high levels of transamination are thereby achieved. These segments are covalently bound to fluorophore groups through linking groups that are transaminated preferably chaotropically into the segments.Type: GrantFiled: August 19, 1993Date of Patent: April 9, 1996Inventors: Michael L. Bittner, Lucy M. Stols, Clarissa F. Prorok, Kenneth A. Cruickshank